Gen-Wealth Partners’s Cellebrite CLBT Stock Holding History

Gen-Wealth Partners’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,870	Closed	-$85.3K	–	631
2024 Q4	$85.3K	Buy	+3,870	New	+$74.5K	0.04%	303

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Gen-Wealth Partners's CLBT Position: Q1 2025 in Review

Gen-Wealth Partners sold out of Cellebrite (CLBT) in Q1 2025, closing a stake of 3,870 shares — an estimated $85.3K sold.

Gen-Wealth Partners first reported a position in CLBT in Q4 2024 and held it in 1 quarter. The position peaked at $85.3K in Q4 2024. 199 funds tracked by Wall St. Rank hold CLBT as of Q1 2025.

Gen-Wealth Partners reported no remaining Cellebrite position as of Q1 2025 after selling out during the quarter.
Gen-Wealth Partners sold 3,870 Cellebrite shares in Q1 2025, an estimated $85.3K.
Gen-Wealth Partners first reported a position in Cellebrite in Q4 2024 and held it in 1 quarter.
Gen-Wealth Partners's Cellebrite position peaked at $85.3K in Q4 2024.
199 funds tracked by Wall St. Rank held Cellebrite as of Q1 2025.

Based on Gen-Wealth Partners's 13F filing for Q1 2025, filed 13 May 2025.